Literature DB >> 29672739

Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.

Gouri M Koduri1, Chetan Mukhtyar2.   

Abstract

Entities:  

Year:  2019        PMID： 29672739     DOI： 10.1093/rheumatology/key097

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  1 in total

1.  MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE.

Authors:  Cécile Gaujoux-Viala; Christophe Hudry; Elena Zinovieva; Hélène Herman-Demars; René-Marc Flipo
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.